Abstract Polysaccharide K (PSK) is a widely used mushroom extract that has shown anti-tumor and immunomodulatory effects in both preclinical and clinical studies. Therefore, it is important to understand the mechanism of actions of PSK. We recently reported that PSK can activate toll-like receptor 2 and enhances the function of NK cells. The current study was undertaken to study the effect of PSK on gamma delta (cd) T cells, another important arm of the innate immunity. In vitro experiments using mouse splenocytes showed that cd T cells produce IFN-c after treatment with PSK and have upregulated expression of CD25, CD69, and CD107a. To investigate whether the effect of PSK on cd T cells is direct or indirect, purified cd T cells were cultured either alone or together with bone marrow-derived DC in a co-culture or trans-well system and then stimulated with PSK. Results showed that direct cell-to-cell contact between cd T cells and DC is required for optimal activation of cd T cells. There was also reciprocal activation of DC by PSK-activated cd T cells, as demonstrated by higher expression of costimulatory molecules and enhanced production of IL-12 by DC in the presence of cd T cells. PSK can also costimulate cd T cells with anti-TCR and anti-CD3 stimulation, in the absence of DC. Finally, in vivo treatment with PSK activates cd T cells among the tumor infiltrating lymphocytes, and depleting cd T cells during PSK treatment attenuated the anti-tumor effect of PSK. All together, these results demonstrated that cd T cells are activated by PSK and contribute to the anti-tumor effect of PSK.
Introduction
It is reported that complementary and alternative medicine (CAM) are widely pursued by cancer patients, ranging from 31 to 64 % in different countries [1, 2] . Medicinal mushrooms are among the commonly used natural products by cancer patients, especially in Asian countries [3, 4] . Polysaccharide K (PSK) is a hot water extract of Trametes versicolor and is a prescription drug in Japan [5] . It has shown anti-tumor efficacy in both preclinical and some clinical studies. For example, a meta-analysis of data from 1,094 patients has shown that PSK as an adjuvant to chemotherapy improved both overall and disease-free survival of patients with colorectal cancer [6] . Therefore, it is important to understand the mechanism of action of this product. Our recent study has shown that PSK activates toll-like receptor 2 (TLR2) and enhances the function of DC and NK cells [7] . The current study is undertaken to investigate the effect of PSK on gamma delta (cd) T cells, another important arm of the innate immunity.
Gamma delta (cd) T cells are a minor population of peripheral T cells and only account for 2-5 % of total T cells in the peripheral blood, yet they have been shown to play an important role in anti-tumor immunity [8] . They recognize their targets independent of major histocompatibility complex (MHC)-mediated antigen presentation and are considered as part of the innate immunity. cd T cells can recognize stress-induced antigens on tumor cells such as MICA/B in human and Rae-1 in mice [9, 10] . Mice deficient for cd T cells are more susceptible to the development of chemically induced cutaneous tumors and spontaneous prostate cancers [10, 11] . cd T cells have been isolated from human tumors and have been shown to react in vitro to tumor cells but not healthy cells [8] . Activated cd T cells can produce large amounts of IFN-c, a cytokine that is critical to anti-tumor immune response [12] . The cytotoxicity of cd T cells against a range of tumor cell lines has been demonstrated and appears to be greater than ab T cells, so adoptive therapy using cd T cells is being actively pursued [13] [14] [15] . In vivo activation of human cd T cells using zoledronic acid followed by adoptive transfer of ex vivo expanded cd T cells is an attractive strategy for cancer immunotherapy and is currently evaluated in both preclinical and clinical studies [8, [16] [17] [18] [19] . Novel agents that can enhance cd T cell function will be useful in cancer immunotherapy.
It has recently been shown that the expression of TLRs, especially TLR2, TLR3, and TLR4, can be detected on cd T cells, and TLR agonists may modulate the function of cd T cell, as summarized in a recent review by Wesch et al. [20] . Based on our recent discovery that PSK activates TLR2, we hypothesize that PSK may modulate the function of cd T cells. Using neu-transgenic mice, a model of HER2
? breast cancer, the current study aims to investigate the effect of PSK on cd T cells, the potential mechanism, and the role of cd T cells in the anti-tumor effect of PSK. Results from this study not only help us understand the immunomodulatory and anticancer effects of PSK, but also reveal the potential of using natural products to modulate cd T cell function for cancer immunotherapy.
Materials and methods

Animals
A colony of neu-transgenic mice [strain name, FVB/NTgN (MMTVneu)-202Mul] was established in our animal facilities from breeding pairs obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained as previously described [21] . All of the procedures were performed in compliance with the University of Washington Institutional Animal Care and Use Committee guidelines.
Antibodies and other reagents
Fluorochrome-conjugated monoclonal antibodies against CD3, cd TCR, CD25, CD69, IFN-c, and CD107a were from eBiosciences (San Diego, CA). Phosphate-buffered saline (PBS), penicillin-streptomycin, and L-glutamine were obtained from Invitrogen Life Technologies (Grand Island, NY). PSK was purchased from Kureha Pharmaceuticals (Japan). PSK was dissolved in PBS at a stock concentration of 10 mg/ml. Aliquots of 100 ll were stored at -80°C. The frozen aliquots were thawed immediately before use.
Measurement of PSK-induced IFN-c production and cd T cell activation in splenocytes
Total splenocytes from neu-transgenic mice were stimulated with PSK (25-400 lg/ml) for 24 h, and the culture supernatant was collected for IFN-c measurement using an ELISA kit from eBiosciences. To determine the cellular source of PSK, intracellular staining of IFN-c was performed using similar method as described before [7] . Brefeldin A (5 lg/ml, Sigma-Aldrich), a secretion inhibitor, was included during the last 16 h of the 48-h incubation in complete RPMI with or without PSK (100 lg/ml). At the end of the activation, the cells were first stained with fluorophore-conjugated antibodies to surface markers. After subsequent fixation and permeabilization, the cells were stained with anti-IFN-c-PE. Samples were acquired on FACS Canto II. List mode files were analyzed using FlowJo (Treestar, OR). The expression of CD25 and CD69 on cd T cells was measured after 24 or 48 h of stimulation with PSK.
CD107a degranulation assay
The degranulation of cd T cells was measured by the expression of CD107a, lysosome-associated membrane protein-1 (LAMP-1). In brief, splenocytes were treated with PSK (100 lg/ml) or medium alone for 6 h. AntiCD107a-PE antibody was added directly to the co-cultures.
After 1-h incubation, brefeldin A was included to the culture and incubated for another 5 h. Cells were then stained with mAbs for CD3 and cd TCR and analyzed on FACS Canto II.
Co-culture of cd T cells with bone marrow-derived DC (BMDC) and PSK stimulation Bone marrow cells were collected from neu-transgenic mice and filtered through a 0.7-lm cell strainer. ACK solution was used to lyse red blood cells, and remaining cells were added to a 6-well plate for 4 h. Non-attached cells were removed, and fresh culture medium (20 ng/ml IL-4 ? 20 ng/ml GM-CSF) was added. On Day 3, nonattached cells were collected and replaced with fresh medium that was added back to the culture. On Day 7, cells were harvested. cd T cells were MACS-enriched from splenocytes using the cd T cell isolation kit (Miltenyi) and cultured in 96-well round-bottom plates coated with antimouse CD3e (5 lg/ml) in complete RPMI medium plus rIL-2 (20 U/ml) for 3-4 days. Cells were then transferred to uncoated wells, and fresh medium was added (complete medium ? rIL-2) for 3 more days. Both BMDCs and cd T cells were harvested and added to 24-well plates at 10 5 cells/well at 1:1 ratio. For trans-well (0.4 lm pore size) inserts, cd T cells were placed in the lower chamber and BMDCs were placed in the upper chamber. PSK (100 lg/ ml) was added to the RPMI medium, and cells were incubated for 24 and 48 h. At the end of incubation, culture supernatant was harvested for analysis of IFN-c by ELISA and the cells were harvested and stained for CD25-APC, CD69-PE-Cy7 to measure activation of cd T cells. Intracellular staining of IFN-c and CD107a expression was also performed similarly as described above, except that both brefeldin A (5 lg/ml) and monensin (5 lg/ml) were included as secretion inhibitors. To measure the activation of BMDC by PSK in the presence or absence of cd T cells, BMDC culture alone or BMDC-cd T cell co-culture was treated with PSK (100 lg/ml) for 24 or 48 h in 96-well flatbottom plates. The expression of CD40 and CD86 on DC was measured by FACS at the end of the treatment. The secretion of IL-12p40 and IL-12p70 into culture supernatant was measured by ELISA using kits from eBiosciences.
Culture of purified cd T cells and PSK co-stimulation with anti-cd TCR or anti-CD3 mAb MACS-purified cd T cells were cultured in complete RPMI in 96-well plates at 2 9 10 5 cells/well. Some of the wells were coated with anti-cd TCR mAb (clone UC7-13D5, 5 lg/ml) or anti-CD3 mAb (clone 145-2C11, 5 lg/ml). PSK (100 lg/ml) was added to the RPMI medium, and cells were incubated for 24 and 48 h. At the end of incubation, culture supernatant was harvested for IFN-c ELISA.
Treatment of tumor-bearing mice with PSK and selective depletion of cd T cells Neu-transgenic mice received subcutaneous implant of 1 million MMC cells, a cell line derived from a syngeneic spontaneous breast cancer in these mice [22] . To measure the in vivo activation of cd T cells, the mice with implanted MMC tumors (average size &600 mm 3 , n = 8 per group) received a single intratumoral injection of PSK (1 mg, dissolved in 100 ll of PBS) or control PBS on Day 1 and tumors were harvested 48 h after the PSK treatment. Tumor infiltrating lymphocytes (TIL) were isolated as previously described [21] . FACS analysis was performed to measure the activation status of cd T cells in TIL and splenocytes after staining with anti-CD3, cd TCR, and CD69 mAbs. To determine the role of cd T cells in the anti-tumor effects of PSK, mice started PSK treatment (100 mg/kg, oral gavage, 3 times per week) when the tumors became palpable and the treatment continued for 4 weeks. Mice in the control group received oral gavage of PBS of the same volume. Mice in the cd T cell depletion group received hamster anti-mouse anti-cd TCR mAb (clone UC7-13D5, 200 lg, i.p., twice a week) during PSK treatment to deplete cd T cells. Mice in the control group received a control hamster IgG during PSK treatment. Tumors were measured every other day with vernier calipers, and tumor volume was calculated as the product of length 9 width 9 height 9 0.5236. In vivo data are presented as mean ± sem of each treatment group (n = 5 per group).
Statistical analysis
Statistical analysis was performed using GraphPad Software (San Diego, CA). Data were analyzed using the twotailed Student's t test or Mann-Whitney test. A value of p \ 0.05 was considered statistically significant.
Results
PSK induces IFN-c production and CD107a degranulation of cd T cells in splenocytes
When total splenocytes from neu-transgenic mice were stimulated with PSK (25-400 lg/ml, 24 h), there was a dose-dependent induction of IFN-c (Fig. 1a) . Intracellular staining showed that NK cells and cd T cells, but not ab T cells, were the major producers of PSK-induced IFN-c (Fig. 1b) . The effect of PSK on NK cells has been previously reported by our group and others [7, 23, 24] , so the current study focused on the effect of PSK on cd T cells. The activation of cd T cells was demonstrated by up-regulated expression of CD25 and CD69 after PSK treatment (Fig. 1c, d) . Interestingly, the expression of CD25 and CD69 on ab T cells was not significantly affected by PSK treatment (data not shown), suggesting cd T cells might be more sensitive to PSK treatment than ab T cells. The preferential activation of cd T cells over ab T cells was observed at different doses of PSK tested (10, 50, or 100 lg/ml, Supplemental Figure 1 ). PSK also induced CD107a expression in cd T cells. As shown in Fig. 2a, b , the percentage of CD107a-positive cd T cells among total cd T cells are 16.3 ± 3.5 % in control group and 41.0 ± 1.3 % (p = 0.0002 from control) in splenocytes treated with PSK (100 lg/ml, 6 h) (Fig. 2b) .
Direct contact between cd T cells and DC is required for optimal activation of cd T cells by PSK To investigate whether the effect of PSK on cd T cells is direct or indirect via activation of DC, we used PSK to treat MACS-purified cd T cells, co-culture of purified cd T cells and BMDC, or trans-well culture of purified cd T cells and BMDC. The activation of cd T cells was measured after 24-or 48-h stimulation with PSK (100 lg/ml). As shown in very low-level induction of CD25 and CD69. PSK treatment of cd T cells and DC co-culture (in the same culture well), but not trans-well culture, resulted in optimal activation of cd T cells (Fig. 3a, b) , indicating that direct cellto-cell contact between cd T cells and DC is required for the activation of cd T cells by PSK. In the cd T cells alone and trans-well cultures, the low-level induction of CD25 and CD69 on cd T cell culture is only observed after treatment with high dose of PSK (100 lg/ml). In the cd-DC co-culture system, even low dose of PSK (10 lg/ml) resulted in significant induction of CD25 and CD69 (Fig. 3c) . Measurement of IFN-c production in cd T cells cultured alone or in the presence of BMDC yielded results consistent with CD25 and CD69 expression, and the optimal induction of IFN-c was only observed in the co-culture system (Fig. 4a) . The percentages of IFN-c ? cd T cells in the co-culture were significantly higher than those in the cd T cells alone or cd-DC trans-well culture (Fig. 4b) . ELISA measurement of IFN-c level in culture supernatant confirmed that cd ? DC co-culture produced the highest level of IFN-c in response to PSK. As shown in Fig. 4c , PSK (100 lg/ml, 24 h)-treated cd ? DC co-culture produced 2,372 ± 790 pg/ml IFN-c, significantly higher than PSKtreated cd T cells alone (48 ± 16 pg/ml) or PSK-treated cd-DC trans-well culture (303 ± 114 pg/ml). PSK also induced CD107a expression in purified cd T cells, and the effect is most significant when the cd T cells were cocultured with DC (Supplemental Figure 2) .
We have previously shown that PSK is a TLR2 agonist and the effect of PSK on DC activation is dependent on TLR2 [7] . To investigate the role of TLR2 in cd T cell activation, we used side-by-side culture of cd T cells and BMDC from wild-type C57/B6 mice and cells from TLR2 -/-mice. Results showed that PSK-induced cd T cell activation (as measured by IFN-c release) is significantly decreased in cells from TLR2 -/-mice (Supplemental Figure 3) . Mismatched cultures of cd T cells and BMDC from wild-type or TLR2
-/-mice showed that the presence of TLR2 on DC is more important than TLR2 on cd T cells in the activation effect of PSK. DC activation by PSK in BMDC cultured alone or BMDC co-cultured with cd T cell showed that PSK treatment (10 or 100 lg/ml, 24 h) leads to significantly higher expression of costimulatory molecules, CD40 and CD86, when BMDC is co-cultured with cd T cells (Fig. 5a ). Measurement of IL-12 in culture supernatant showed that in the presence of cd T cells, PSK stimulation resulted in significantly higher production of both IL-12p40 and IL12p70 from DC (Fig. 5b, c) .
PSK co-activates purified cd T cells with TCR crosslinking in the absence of DC It has recently been shown that TLR agonists can activate cd T cells directly by co-stimulating cd T cells with TCR [25] , so we questioned whether PSK and anti-cd TCR mAb can activate cd T cells in the absence of DC. MACSpurified cd T cells were cultured on anti-cd TCR mAbcoated plates in the presence or absence of PSK. As shown in Fig. 6a , the addition of PSK to anti-cd TCR resulted in enhanced IFN-c production (7634 ± 1591 pg/ml IFN-c in cd T cells stimulated with anti-cd TCR alone for 48 h, 12,823 ± 1,293 pg/ml in cd T cells stimulated with anticd TCR and PSK for 48 h, p = 0.04). In a similar fashion, PSK augmented anti-CD3 mAb-induced IFN-c production (Fig. 6b) .
In vivo PSK treatment activates cd T cells in TIL and cd T cell contributes to the anti-tumor effect of PSK Intratumoral injection of PSK resulted in activation of cd T cells in TIL, but not in splenocytes. As shown in Fig. 7a , cd T cells in TIL have significantly higher expression of CD69 after PSK treatment. The expression of CD69 on cd T cells in splenocytes was much lower as compared to that in TIL and showed no difference between PBS and control PSK group (Fig. 7a) . To determine the potential contribution of cd T cells to the anti-tumor effect of PSK, mice were depleted of cd T cells during PSK treatment using a mAb against cd TCR. As shown in Fig. 7b , selective depletion of cd T cells during PSK treatment significantly attenuated the anti-tumor effect of PSK (Fig. 7b) , suggesting that cd T cells contribute to the anti-tumor effect of PSK.
Discussion
There has been a gap between the rapid progress in tumor immunology and our limited understanding of the mechanism of action of natural products. Our study was aimed to address the gap. The recent progress in our understanding of cd T cell regulation indicates TLR agonists can activate cd T cells in a direct or indirect manner [20] . Our study proves that PSK, a natural product with TLR2 agonist activity, can activate cd T cells. To our knowledge, this is the first report on the effect of PSK on cd T cells. These results provide novel insights into the mechanisms of the anti-tumor and immunostimulatory effects of PSK and also indicate the potential of using natural products to augment cd T cell function.
The anti-tumor effects of PSK have been demonstrated in multiple clinical trials conducted in Japan. As an adjuvant to chemotherapy, it has shown beneficial effect on overall and progression-free survival, especially for patients with stomach and colorectal cancer [6, 26, 27] . Understanding the mechanism of action of this product is critically important. Our recent study has shown that PSK activates TLR2 and enhances the function of DC and NK cells [7] . In the current study, we demonstrated that cd T cells are also activated by PSK. We have shown that cd T cells can produce large amounts of IFN-c in response to PSK stimulation ([2 ng/ml). IFN-c plays an important role in promoting anti-tumor immune response and controlling tumor growth [28] . This cytokine also provides a secondary signal for DC activation. As expected, the presence of PSK-activated cd T cells further contributes to DC activation by PSK leading to higher expression of costimulatory molecules and enhanced IL-12 production, which is important for priming of T cell and NK cell responses [29] . This complex interaction between PSK-activated DC, cd T cells, ab T cells, and NK cells might help explain that although our previous studies using selective depletion of CD4, CD8, and NK cells during PSK treatment suggest the anti-tumor effect of PSK is dependent on CD8 T cells and NK cells [7] , the current study using selective depletion of cd T cells suggests cd T cells also contribute to the antitumor effect of PSK. Therefore, this information has improved our understanding of the multi-faceted immunomodulatory effects of PSK.
DC-dependent activation of cd T cells by TLR agonists has previously been reported for TLR3 agonist poly (I:C), TLR4 agonist LPS, and TLR5 agonist flagellin [30, 31] . Devilder et al. [30] reported that poly(I:C), LPS, and flagellin activated human Vc9 Vd2 T cells through a process that strictly required the presence of either myeloid or plasmacytoid DC expressing the relevant TLR, and the response of cd T cells to TLR agonists-treated DC requires type I IFN but not IL-12. Kunzmann et al. [31] also reported that poly (I:C)-mediated activation of cd T cells is indirect and mediated via type I IFN derived from TLR3-expressing CD11c ? DCs. In our study, we observed that the optimal activation of mouse cd T cells by PSK requires the cell-tocell contact between DC and cd T cells. At this point, we do not know what ligand and receptor are involved in PSKinduced cd T cell activation by DC, we hypothesize that NKG2D ligand and receptor might be involved. NKG2D is an important activating receptor on cd T cells [32] [33] [34] . The induction of NKG2D ligand expression by TLR agonists has been reported in other publications [35] [36] [37] . We also observed induction of MICA/B on human DC by PSK but did not observe the induction of mouse NKG2D ligands (Rae-1c or Mult1) by PSK on mouse DC (data not shown), so the ligand(s) involved in PSK-stimulated DC and cd T cell reciprocal activation remains to be identified. Unpublished data from our laboratory have shown that PSK does not induce IFN-a in PBMC, a cytokine that has previously been shown to mediate the DC-dependent activation of human cd T cells [30, 31] . This might explain the lack of activation we observed in the trans-well culture of BMDC and murine cd T cells.
In this study, we also observed DC-independent coactivation of cd T cells with anti-CD3 and anti-TCR stimulation. This is consistent with previous reports that TLR1, 2, and 6 ligands have a direct co-stimulatory effect on human and mouse cd T cells [20, 38, 39] . The publication by Deetz et al. [25] has reported activation of human cd T cells by TLR2 agonist Pam3Cys. Hedges et al. [40] reported that bovine cd T cells can respond directly to LPS and peptidoglycan. As for murine cd T cells, Martin et al. showed that IL-17-producing cd T cells but not other cd T cell express TLR1 and TLR2 and could directly react to PAMP. Interestingly, our study suggests IFN-c producing murine cd T cells are also responsive to TLR2 agonist PSK. Whether the difference could be due to mouse strain or other experimental setting remains to be investigated. In addition to TLR2, mouse cd T cells have been shown to respond to treatment with TLR4 agonist LPS and produce both IFN-c and IL-17, which contributes to the development of experimental autoimmune encephalomyelitis (EAE) [41] . Our current finding on the effect of PSK not only adds to the published literature that TLR agonists can modulate cd T cell function, but also highlights the potential of using natural products to enhance cd T cell function.
Given the important role of cd T cells in anti-tumor immunity, the potential of using natural products to enhance cd T cell function is an area that needs more investigation. Indeed, several studies have shown promising results on the stimulatory effect of natural products on cd T cells. A study by Kamath et al. [42] has shown that oral consumption of a tea component, L-theanine, enhanced cd T cell proliferation and IFN-c secretion. A recent study showed that polysaccharides isolated from Acai fruit induce innate immune response and activate cd T cells in human, mouse, and bovine PBMC cultures [43] . Another study showed that polysaccharides derived from Yamoa (Funtumia elastic) can activate cd T cells from different species and are more potent than LPS in activating human cd T cells [44] . Most of these findings remain to be tested in clinical trials.
Although PSK and other mushroom products have been tested in multiple clinical trials in Asian countries, it has rarely been tested in Western countries. Two recent clinical trials in the United States have tested Grifola frondosa and T. versicolor in breast cancer patients [45, 46] . There is some preliminary evidence that these mushroom products could induce cytokines and modulate NK cell function in vivo [45, 46] . Results from our current study would encourage more studies on the effect of mushroom extracts on human cd T cells. Indeed, some pilot in vitro experiments using human PBMC have shown that PSK-stimulated IFN-c production in human cd T cells (data not shown). However, given the difference in human and murine cd T cells and the functional difference between different subsets of human cd T cells, we cannot simply extrapolate the data from mouse to human. Further investigations are needed on the effect of PSK on human cd T cells. Our group has recently obtained FDA approval to use PSK in clinical trial in cancer patients. Whether cd T cell function may be improved in cancer patients after oral administration of PSK will be evaluated in future studies.
